Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Home
Prognostic Impact Of Circulating Tumor Dna Detection In Portal And Peripheral Blood In Resected Pancreatic Ductal Adenocarcinoma Patients.

Home
Prognostic Impact Of Circulating Tumor Dna Detection In Portal And Peripheral Blood In Resected Pancreatic Ductal Adenocarcinoma Patients.

Related Concept Videos

Related Experiment Video

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Prognostic impact of circulating tumor DNA detection in portal and peripheral blood in resected pancreatic ductal

Charlotte Maulat^1,2,3, Cindy Canivet⁴, Bastien Cabarrou⁵

¹Digestive Surgery, Hepatobiliary and Pancreatic Surgery Department and Liver Transplantation Unit, Toulouse University Hospital, Toulouse, France. maulat.c@chu-toulouse.fr.

Scientific Reports

|November 8, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Detecting circulating tumor DNA (ctDNA) during pancreatic cancer surgery indicates a worse prognosis. Portal vein sampling did not improve ctDNA detection, but tissue mobilization increased ctDNA levels.

Keywords:

Circulating tumor DNA Liquid biopsy Overall survival Pancreatic ductal adenocarcinoma Recurrence-free survival Tissue mobilization

More Related Videos

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Published on: November 5, 2020

Related Experiment Videos

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Published on: November 5, 2020

Area of Science:

Oncology
Molecular Diagnostics
Surgical Oncology

Background:

Prognostic significance of circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma (PDAC) requires further validation.
Understanding ctDNA kinetics and the impact of surgical manipulation is crucial for improving patient outcomes.

Purpose of the Study:

To investigate ctDNA kinetics in portal and peripheral blood before and after resection in PDAC patients.
To determine if tissue mobilization during surgery influences ctDNA detection and its prognostic value.
To assess the utility of portal vein sampling for ctDNA detection compared to peripheral blood.

Main Methods:

Prospective single-center cohort study involving 34 PDAC patients undergoing pancreaticoduodenectomy.
Collection of portal and peripheral blood samples intraoperatively (before and after tissue mobilization) and postoperatively for 12 months.
Next-generation sequencing for tumor mutation identification and digital droplet PCR for ctDNA detection.

Main Results:

Intraoperative ctDNA detection in either portal or peripheral blood was significantly associated with worse recurrence-free survival (RFS) and overall survival (OS).
Portal vein sampling did not offer improved ctDNA detection compared to peripheral blood.
Tissue mobilization during surgery led to a 2.5-fold increase in peripheral blood ctDNA levels, though not significantly linked to RFS or OS.

Conclusions:

Intraoperative ctDNA detection is a significant negative prognostic marker in resected PDAC patients.
Surgical tissue mobilization transiently increases ctDNA levels, highlighting the dynamic nature of ctDNA during surgery.
Peripheral blood ctDNA monitoring, particularly around surgical manipulation, warrants further investigation for prognostic and potentially therapeutic implications.